the ceo of a pharmaceutical company asked his consultant if it was a good idea to implement the s-curve model to predict when a technology would reach its limits. the consultant identified a limitation in the use of the model. which of the following is most likely the limitation identified by the consultant? firms cannot influence the shape of the s-curve through their developmental activities. unexpected changes in the market can alter the shape of a technology's s-curve. s-curve models cannot be applied in the pharmaceutical industry. s-curve models are outdated and unrealistic.